|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Oncogene MYC is deregulated in many human cancers, especially in lymphoma.
|
25692307 |
2015 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
More recently, MYC rearrangement with multiple copies/gain of BCL2 or multiple copies/gain of MYC with a BCL2 rearrangement have been described and exhibit a very similar clinical course to conventional double-hit lymphomas.
|
27391453 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The c-myc gene was found to be rearranged in two lymphomas, an African Burkitt's lymphoma and a non-Hodgkins lymphoma in leukemic phase.
|
6330529 |
1984 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this review, we summarize two sessions dedicated to "high-grade B cell lymphomas, with MYC and BCL2 and/or BCL6 rearrangements (so-called double/triple-hit lymphomas)" and "high-grade B cell lymphomas, NOS" as defined in the 2016 update of the WHO lymphoma classification, Burkitt lymphoma and related neoplasms, and terminally differentiated aggressive B cell lymphomas.
|
28844114 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The oncogenic activation of MYC in these lymphomas may be an important pathogenetic element associated with EBV infection.
|
20962620 |
2010 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Indeed, previous studies using gene-targeted mice revealed that BCL-XL, but surprisingly not BCL-2, is critical for the development of c-MYC-induced pre-B/B lymphomas.
|
26962682 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we provide biological insight on the function of MYC-regulated miRNAs, the mechanisms of MYC-induced miRNA repression, and the complicated feedback circuitry underlying lymphoma progression, as well as potential therapeutic targets in aggressive B-cell lymphomas.
|
24394940 |
2014 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Rearrangements of the c-MYC proto-oncogene and mutations of the p53 tumor suppressor gene have also been documented in these lymphomas.
|
8274734 |
1994 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Biological feature validation of estimated gene interaction networks from microarray data: a case study on MYC in lymphomas.
|
21498549 |
2011 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Isolated BCL2 and MYC rearrangements were not predictive of outcome in our patients as a whole, but only in those with the germinal center subtype of lymphoma.
|
22929980 |
2013 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recognition and proper management of patients with MYC-altered lymphomas is crucial to improving patient outcomes.
|
26983958 |
2016 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
They also negatively correlated with the overall survival of patients with lymphoma in the same way that MYC levels do.
|
22546857 |
2012 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The latest revision of lymphoma's World Health Organization classification describes the new provisional entity "Burkitt-like lymphoma with 11q aberration" (BLL, 11q) as lacking MYC rearrangement, but harboring the specific11q-gain/loss aberration.
|
29272887 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In mouse models, MYC induces lymphomas, but requires cooperation with other lesions, including inactivation of the p53 pathway, structural alterations of BCL2 family members, or increased PI3K activity.
|
25199984 |
2014 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that co-inhibition of MYC and BCL2 signaling is a promising therapeutic strategy for patients with DHL/THL lymphomas.
|
25916698 |
2015 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Both primary breast lymphoma and lymphoma with concurrent BCL2-IGH and MYC translocations are rare and are primarily seen in adult patients.
|
21491965 |
2012 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The unique B-cell genotype configuration and the C-MYC activation suggested that the cellular origin of this rare case of malignant lymphoma with a T-cell phenotype was quite immature lymphocytes.
|
9494610 |
1998 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
|
20823132 |
2010 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The striking parallels between the behavior of tumor-derived mutations in disparate regions of the MYC protein reveals that a common molecular process is disrupted by these mutations, implying an active role for these mutations in tumorigenesis and suggesting that different therapeutic strategies may be needed for treatment of lymphomas expressing wild type versus mutant forms of MYC protein.
|
24998853 |
2015 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas).
|
21560251 |
2011 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of one allele of KAT6A extends the median survival of mice with MYC-induced lymphoma from 105 to 413 days<sup>11</sup>.
|
30069049 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
BCL2(+)/MYC(+) lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1).
|
19597184 |
2009 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with neoplasms characterized by extra MYC signals plus IGH@BCL2 (n=6) or MYC rearrangement with extra BCL2 signals (n=2) had overall survival ranging from 1.7 to 49 months, similar to patients with MYC/BCL2 lymphomas.
|
22002575 |
2012 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, targeting SUMOylation represents an attractive therapeutic option for lymphomas with MYC involvement.
|
25143484 |
2014 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
|
18765521 |
2008 |